Company Profile
Regeneron Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- REGN
- Exchange:
- NASDAQ
- Sector:
- Antibody Drugs, Biopharma
- Location:
- United States
Stock performance
772.11 USD (+0.46%)
Close
Last updated: August 6, 2026
63.2B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, REGN closed up 0.46% at $772.11. No new same-company headline was identified in the current news window.
Company overview
Integrated Biopharmaceutical Company
Regeneron Pharmaceuticals discovers, develops, manufactures and commercializes medicines across ophthalmology, immunology, oncology, rare disease, cardiovascular medicine and other areas. Its internal technology platforms support a large clinical portfolio and multiple global collaborations.
Retinal Disease Franchise
EYLEA and EYLEA HD are anti-VEGF therapies used in retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema. EYLEA HD offers extended dosing intervals and anchors Regeneron’s ophthalmology business.
Dupixent Collaboration
Dupixent is an IL-4 receptor alpha antibody developed globally with Sanofi across type 2 inflammatory diseases. Its indications span dermatologic, respiratory and allergic conditions, including recent expansions into pediatric chronic spontaneous urticaria and allergic fungal rhinosinusitis.
Oncology Pipeline
Regeneron commercializes the PD-1 antibody Libtayo and is developing fianlimab, a LAG-3 antibody, with cemiplimab in metastatic and adjuvant melanoma. The company’s oncology strategy combines proprietary antibodies across complementary immune pathways.
Rare-Disease Medicines
Otarmeni is an approved AAV gene therapy for OTOF-related severe-to-profound hearing loss. Garetosmab, an Activin A antibody, is under regulatory review for fibrodysplasia ossificans progressiva, while cemdisiran is an siRNA therapy submitted for myasthenia gravis.
Cardiovascular and Metabolic Programs
REGN7508 and REGN9933 are Factor XI antibodies in Phase 3 development for thrombosis prevention. Mibavademab is a leptin-receptor agonist antibody in Phase 3 testing for monogenic obesity.
Future catalysts
FDA decisions on EYLEA HD prefilled-syringe manufacturing applications anticipated in the second quarter of 2026.
Phase 3 first-line metastatic-melanoma results for fianlimab plus cemiplimab expected in the second quarter of 2026.
Second interim or final analysis of the adjuvant-melanoma fianlimab study expected in the second half of 2026.
FDA action on the garetosmab BLA for FOP targeted for August 2026.
FDA filing acceptance for cemdisiran anticipated in the second quarter of 2026, with a decision expected in the fourth quarter.
Additional Phase 3 Factor XI antibody studies planned later in 2026.
Recent news
- 01
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Source: Regeneron Pharmaceuticals
- 02
Regeneron Reports Second Quarter 2026 Financial and Operating Results
Source: Regeneron Pharmaceuticals
- 03
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
Source: Regeneron Pharmaceuticals
- 04
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Source: Regeneron Pharmaceuticals
- 05
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Source: Regeneron Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals (REGN) most recently closed at 772.11 USD, a +0.46% move versus the previous session.
What is the market cap of Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals currently has a market capitalization of 63.2B USD on BioPharmSignal.
What does Regeneron Pharmaceuticals do?
Integrated Biopharmaceutical Company Regeneron Pharmaceuticals discovers, develops, manufactures and commercializes medicines across ophthalmology, immunology, oncology, rare disease, cardiovascular medicine and other areas. Its internal technology platforms support a large clinical portfolio and multiple global collaborations. Retinal Disease...
On which exchange is REGN stock listed?
Regeneron Pharmaceuticals (REGN) is associated with NASDAQ, United States, Antibody Drugs, Biopharma.
What is IL-4?
Dupixent Collaboration Dupixent is an IL-4 receptor alpha antibody developed globally with Sanofi across type 2 inflammatory diseases.
Which conditions is Regeneron Pharmaceuticals targeting with IL-4?
Regeneron Pharmaceuticals is associated with oncology, immunology, rare disease based on its company overview and current catalyst commentary.
How does Regeneron Pharmaceuticals describe recent progress with IL-4?
FDA decisions on EYLEA HD prefilled-syringe manufacturing applications anticipated in the second quarter of 2026. Phase 3 first-line metastatic-melanoma results for fianlimab plus cemiplimab expected in the second quarter of 2026. Second interim or final analysis of the adjuvant-melanoma fianlimab study expected in the second half of 2026. FDA action on the...
What is PD-1?
Oncology Pipeline Regeneron commercializes the PD-1 antibody Libtayo and is developing fianlimab, a LAG-3 antibody, with cemiplimab in metastatic and adjuvant melanoma.